Manufacturers report positive results for ibrexafungerp for vulvovaginal candidiasis

In the VANISH-306 study 63.3% of patients given ibrexafungerp (an oral glucan synthase inhibitor) had a complete resolution of vaginal signs and symptoms at day 10, with 58.5% having a mycological eradication.

Source:

Biospace Inc.